Intravenous immunoglobulin, or IVIG, is essentially a plasma product.
Intravenous immunoglobulin, or IVIG, is essentially a plasma product. It is used for treating patients having antibody deficiencies, and is created from serum obtained from several thousand donors per batch. Immune globulin products derived from human blood was first utilized in 1953 in order to provide a treatment to primary stages of immune deficiencies. IVIG primarily consists of immunoglobulin G, purified and extracted from human plasma, having intact Fc-independent effector functions. It also consists of small amounts of immunoglobulin A or Immunoglobulin M.
Read Report overview - https://www.transparencymarketresearch.com/intravenous-immunoglobulin-market.html
Medically, use of IVIG has had a substantial impact in fields such as haematology, nephrology, dermatology, rheumotolgy, and neurology. The product is utilized in the treatment of several chronic ailments such as uveitis, systematic lupus erythematosis, and vasculitis. Recently, there have been several significant advances in the field. For instance, a recent study demonstrates how IVIG is able to suppress the proliferation of antigen-specific cells, while avoiding the induction of apoptosis by litigation.
According to TMR, these are the 3 key factors impacting the global IVIG market:
- Low Side Effects
The use of intravenous immunoglobulin has visibly a lower amount of side-effects. The immediate side effects include chills and flu. Serious side effects typically occur in patients who take the medicines regularly or in high doses. Till now, less than 5% of users have encountered severe side effects. The effectivity of IVIG combined with lower occurrence rate of side-effects is a key factor boosting the growth of the global IVIG market over the coming years.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1930
- Growing Incidence of Autoimmune Diseases
Autoimmune diseases are one of the leading reasons for death in women and female children in all age groups up to the age of 64 years. The National Institute of Health estimates that up to 23.5 million Americans suffer from one or the other autoimmune disease. The rising prevalence and severity of autoimmune conditions are expected to augment the demand for IVIG in the coming years.
- High Adoption of Home Care Services
Nowadays, patients prefer receiving IVIG infusions at home. This not only offers them convenience, but also an improved quality of life, enabling them better control over routine activities. Additionally, IVIG infusions through home care services is leading to a reduction in scheduling clashes for patients.
Request For Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1930
Geographically, North America led the global intravenous immunoglobulin market in 2017. The U.S. FDA recently included approval for payments to plasma donors in order to boost plasma donation. This is a pivotal factor driving the market in the region. Asia Pacific accounted for a significant share of the market in 2017, on account of high prevalence of diseases, incrementing spending on health care, and growing geriatric population. The regions also comprises of a large patient pool, high population density, and steadily developing infrastructure. This is expected to augment demand for IVIG in the region.
The competitive ecosystem of the global intravenous immunoglobulin market is a consolidated one, with vendors competing on the basis of product efficiency, solid pipelines, and swift action.
Key vendors operating in the global IVIG market are CSL Behring LLC, Grifols, S.A., Shire plc, China Biologic Products, Inc., and Octapharma AG.
Request for Discount on this Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1930
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/